Unknown PHASE4 INTERVENTIONAL 2-arm NCT00896831

Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy (PORTOALEGRE)

Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study

Sponsor: Hospital de Clinicas de Porto Alegre

Conditions Hepatic Encephalopathy

Interventions L-ornithine-L-aspartate placebo

Updated 6 times since 2017 Last updated: Jun 5, 2009 Started: Nov 30, 2008 Primary completion: Mar 31, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00896831, this PHASE4 trial focuses on Hepatic Encephalopathy and remains ongoing. Sponsored by Hospital de Clinicas de Porto Alegre, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Enrolling By Invitation → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE4

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital de Clinicas de Porto Alegre

Data source: Hospital de Clinicas de Porto Alegre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Porto Alegre, Brazil